DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$83.45
8.91 (11.95%)
▲
5d:
+16.65%
30d:
+21.19%
90d:
+40.13%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Smart Money Distribution
None View Scanner →
Strength: 5.8/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DXCM is 9.4% above its trading range ($76.30). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DXCM is 9.4% above its trading range ($76.30). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.82
Based on 11.5% avg growth
INTRINSIC VALUE TODAY
$78.75
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $83.45, which is considered extended relative to its 30-day fair value range of $69.57 to $76.30. From a valuation perspective, the stock is trading at a premium (Forward PE: 27.1) compared to its historical average (24.1). At these levels, the market is pricing in 4.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a uptrend. The price is approaching resistance at $84.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.0% recently.
Market Sentiment: DXCM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DXCM is in a uptrend. The price is approaching resistance at $84.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.0% recently.
Market Sentiment: DXCM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$69.57 -
$76.30
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+9.4% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.0%)
- NEUTRAL: Near Wall St target ($86.16)
- NEUTRAL: Market pricing in 4.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$69.57 -
$76.30
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$69.79
Resistance Level
$84.70
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.12
Wall Street Target
$86.16
(+3.2%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Premium vs History
+4.0% premium
PE vs Historical
27.1 vs 24.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$86.79
(+4%)
2-Year Target
$90.26
(+8%)
3-Year Target
$93.87
(+13%)
3-Yr Target (if PE normalizes)
(PE: 27→24)
PE COMPRESSION
$83.43
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.1, Growth: 18.9%)
$140.27
(+68%)
Base:
(SPY PE: 20.7, Growth: 18.9%)
$107.24
(+29%)
Bear:
(PE: 17.6, Growth: 18.9%)
$91.15
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 32.27 | Current EPS (TTM): $2.31
Bull Case
$109.24
(+31%)
Analyst growth 33.2%, PE expands to 35.5
Base Case
$99.31
(+19%)
Market implied 33.2%, PE stable at 32.3
Bear Case
$50.69
(-39%)
Severe decline -20.0%, PE contracts to 27.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 02, 2026 12:45 PM ET
Data refreshes hourly during market hours. Next update: 1:45 PM
Data refreshes hourly during market hours. Next update: 1:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$64 | 55 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 57 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$236 | 51 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 52 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
